Role of Nicotine Dependence on the Relationship between Variants in the Nicotinic Receptor Genes and Risk of Lung Adenocarcinoma

Abstract

<div><p>Several variations in the nicotinic receptor genes have been identified to be associated with both lung cancer risk and smoking in the genome-wide association (GWA) studies. However, the relationships among these three factors (genetic variants, nicotine dependence, and lung cancer) remain unclear. In an attempt to elucidate these relationships, we applied mediation analysis to quantify the impact of nicotine dependence on the association between the nicotinic receptor genetic variants and lung adenocarcinoma risk. We evaluated 23 single nucleotide polymorphisms (SNPs) in the five nicotinic receptor related genes (<i>CHRNB3, CHRNA6, and CHRNA5/A3/B4</i>) previously reported to be associated with lung cancer risk and smoking behavior and 14 SNPs in the four ‘control’ genes (<i>TERT</i>, <i>CLPTM1L, CYP1A1</i>, and <i>TP53</i>), which were not reported in the smoking GWA studies. A total of 661 lung adenocarcinoma cases and 1,347 controls with a smoking history, obtained from the Environment and Genetics in Lung Cancer Etiology case-control study, were included in the study. Results show that nicotine dependence is a mediator of the association between lung adenocarcinoma and gene variations in the regions of <i>CHRNA5/A3/B4</i> and accounts for approximately 15% of this relationship. The top two <i>CHRNA3</i> SNPs associated with the risk for lung adenocarcinoma were rs1051730 and rs12914385 (p-value = 1.9×10⁻¹⁰ and 1.1×10⁻¹⁰, respectively). Also, these two SNPs had significant indirect effects on lung adenocarcinoma risk through nicotine dependence (p = 0.003 and 0.007). Gene variations rs2736100 and rs2853676 in <i>TERT</i> and rs401681 and rs31489 in <i>CLPTM1L</i> had significant direct associations on lung adenocarcinoma without indirect effects through nicotine dependence. Our findings suggest that nicotine dependence plays an important role between genetic variants in the <i>CHRNA5/A3/B4</i> region, especially <i>CHRNA3,</i> and lung adenocarcinoma. This may provide valuable information for understanding the pathogenesis of lung adenocarcinoma and for conducting personalized smoking cessation interventions.</p></div